Alluvi, formerly BI 4744, presents a promising breakthrough in obesity treatment. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide targets demonstrates https://alluvi-healthcare939178.law-wiki.com/user